open access

Vol 12, No 1 (2008)
Prace oryginalne
Published online: 2008-01-28
Get Citation

Eprosartan - effect on quality of life in patients with essential hypertension

Marek Klocek, Kalina Kawecka-Jaszcz
Nadciśnienie tętnicze 2008;12(1):20-27.

open access

Vol 12, No 1 (2008)
Prace oryginalne
Published online: 2008-01-28

Abstract

Background The goal of the study was to evaluate antihypertensive efficacy and the quality of life (QoL) in hypertensive patients treated with an angiotensin II receptor antagonist - eprosartan, both in mono- or in combination therapy.
Material and methods The study population consisted of 85 patients with mild to moderate essential hypertension (47 men and 38 women), age 45.1 ± 13.9 yrs. Mean SBP was 154.0 mm Hg and DBP was 99.2 mm Hg. At baseline 16 patients (18.6%) were untreated, and 70 (81.4%) were treated with monotherapy: thiazide-like diuretic (14 pts), beta-blocker (13 pts), ACE inhibitor (20 pts), calcium antagonist (18 pts), alpha-blocker (2 pts), centrally acting drug (3 pts). BP and heart rate were measured at baseline and on each control visit (every 4 weeks for 16 weeks). In all patients eprosartan 600 mg once daily was used. In patients who did not reach BP control (BP < 140/90 mm Hg) after 8 weeks, hydrochlorothiazide (HCTZ) 12.5 mg daily was added. QoL was evaluated at baseline and after 16 weeks by the Psychological General Well-being Index questionnaire (PGWB).
Results After 16 weeks of treatment with eprosartan. BP was significantly decreased (154.0/99.2 vs. 129.4/85.1 mm Hg, p < 0.01), both in men and in women. At the end of the study in all patients blood pressure control was obtained. HCTZ was added to 14 patients (16.5%) during the study. Most pronounced reduction of BP was observed in patients treated with eprosartan + thiazide-like diuretic, eprosartan + calcium antagonist and eprosartan + ACE inhibitor. After 16 weeks significant improvement of QoL (PGWB 88.4 ± 9,1 vs. 101.4 ± 10,3 points, p < 0.01) was observed. The total score of the PGWB and its subscales improved significantly in both sexes, except of “self-control” subscale.
Conclusions Eprosartan provides good antihypertensive efficacy and significantly improves quality of life, irrespective of gender. Higher QoL during treatment with eprosartan is strictly related to better blood pressure control.

Abstract

Background The goal of the study was to evaluate antihypertensive efficacy and the quality of life (QoL) in hypertensive patients treated with an angiotensin II receptor antagonist - eprosartan, both in mono- or in combination therapy.
Material and methods The study population consisted of 85 patients with mild to moderate essential hypertension (47 men and 38 women), age 45.1 ± 13.9 yrs. Mean SBP was 154.0 mm Hg and DBP was 99.2 mm Hg. At baseline 16 patients (18.6%) were untreated, and 70 (81.4%) were treated with monotherapy: thiazide-like diuretic (14 pts), beta-blocker (13 pts), ACE inhibitor (20 pts), calcium antagonist (18 pts), alpha-blocker (2 pts), centrally acting drug (3 pts). BP and heart rate were measured at baseline and on each control visit (every 4 weeks for 16 weeks). In all patients eprosartan 600 mg once daily was used. In patients who did not reach BP control (BP < 140/90 mm Hg) after 8 weeks, hydrochlorothiazide (HCTZ) 12.5 mg daily was added. QoL was evaluated at baseline and after 16 weeks by the Psychological General Well-being Index questionnaire (PGWB).
Results After 16 weeks of treatment with eprosartan. BP was significantly decreased (154.0/99.2 vs. 129.4/85.1 mm Hg, p < 0.01), both in men and in women. At the end of the study in all patients blood pressure control was obtained. HCTZ was added to 14 patients (16.5%) during the study. Most pronounced reduction of BP was observed in patients treated with eprosartan + thiazide-like diuretic, eprosartan + calcium antagonist and eprosartan + ACE inhibitor. After 16 weeks significant improvement of QoL (PGWB 88.4 ± 9,1 vs. 101.4 ± 10,3 points, p < 0.01) was observed. The total score of the PGWB and its subscales improved significantly in both sexes, except of “self-control” subscale.
Conclusions Eprosartan provides good antihypertensive efficacy and significantly improves quality of life, irrespective of gender. Higher QoL during treatment with eprosartan is strictly related to better blood pressure control.
Get Citation

Keywords

arterial hypertension; quality of life; eprosartan

About this article
Title

Eprosartan - effect on quality of life in patients with essential hypertension

Journal

Arterial Hypertension

Issue

Vol 12, No 1 (2008)

Pages

20-27

Published online

2008-01-28

Bibliographic record

Nadciśnienie tętnicze 2008;12(1):20-27.

Keywords

arterial hypertension
quality of life
eprosartan

Authors

Marek Klocek
Kalina Kawecka-Jaszcz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl